LATEST ALERTS
Philip Morris International (PMI)’s net revenues were up by 10% in the first half of 2021, with smoke-free products accounting for 28.5% of the total
The latest figures from Swedish Match show continued momentum in smoke-free tobacco alternatives, with nicotine pouches “the driving force”
PMI’s acquisition of Fertin Pharma, a Danish manufacturer of gums and other oral products, indicates the company’s strategy to ensure “corporate survival” in the tobacco-alternatives sector, experts believe
Los Angeles is in the early stages of preparing to ban flavoured tobacco products, the local government having authorised the drafting of a measure to end the sale of such products in the city’s 4,500 tobacco retailers
The US Food and Drug Administration (FDA) has posted a list of over 6m deemed new tobacco products for which it received Premarket Tobacco Product Applications (PMTAs) by the 9th September 2020 deadline
News that Florida is planning to increase the purchase age for tobacco products to 21 is another clear indication of just how much the issues of youth smoking and youth vaping dominate the minds of politicians and regulators
A judge of the US International Trade Commission (ITC) believes Philip Morris International (PMI)’s Iqos heated tobacco sticks infringe patents owned by British American Tobacco (BAT)
The US FDA considers that the Modified Risk Tobacco Product Application (MRTP) for Philip Morris International (PMI)’s Iqos 3 holder and charger is “sufficiently complete” to start a substantive review
The big news from the US Food and Drug Administration last week was a ban on menthol in combustible cigarettes, closing off a loophole that had allowed this one flavour to be marketed even after all others were forbidden. It may not happen any time soon – the agency’s cautiously-worded announcement said only that it is “working toward issuing proposed product standards » Continue Reading.
The information the public receives on tobacco harm reduction and whether it contributes to improving the role of tobacco-alternatives is a hot topic that divides the industry and the scientific community
The US Food and Drug Administration (FDA) has announced plans to ban menthol tobacco in 2022, a “significant step” towards increasing smoking cessation and reducing youth uptake
Altria has confirmed its full-year guidance for 2021 and full acquisition of its nicotine pouches business despite a dip in total company earnings for the first quarter of the year
While Brazil’s health authorities keep postponing a final decision on future regulation of tobacco alternatives, a new proposal to reinforce a nationwide ban on heated tobacco is being considered in the Chamber of Deputies
Philip Morris International (PMI)’s earnings were up slightly in the first quarter of 2021, boosted by a 38% increase in heated tobacco unit volume in Europe
How much information the public receives from health authorities about tobacco harm reduction – and how much it helps – is a hot topic between the industry and the scientific community
Colombia’s Parliament is considering a bill that would impose fresh regulations on the sale and use of tobacco-alternative products, including heated tobacco
Swedish Match posted an operating profit of nearly SEK 7bn ($845m) in 2020, up 23% on the previous year, thanks largely to a good performance by its ZYN nicotine pouches and record US sales The company posted an operating profit of nearly SEK 7bn ($845m) in 2020, an increase of 23% against 2019.
PMI is spreading optimism about its “beyond nicotine” portfolio, aiming to reach $1bn revenue from tobacco-alternatives in less than five years’ time, with an expected increase in the demand of heated tobacco consumables
Demand for Philip Morris International (PMI)’s heated tobacco products rose in 2020, but that was not enough to save the tobacco giant from posting an overall 3.7% drop in net revenues over the year
A patent infringement hearing at the US International Trade Commission (ITC) could result in Philip Morris International (PMI) being barred from importing its Iqos consumables into the US
A coalition of US attorneys called on the US Food and Drug Administration (FDA) to ban menthol cigarettes “in the best interest of the public” and no longer delay a process that has been on stand-by since 2018
Altria has posted positive numbers for the last quarter of 2020 despite the coronavirus pandemic, with a good performance for its oral portfolio but unknown figures for Iqos in the US
The US Food and Drug Administration (FDA) is looking to appoint a new company to provide public communication services to the agency’s Center for Tobacco Products (CTP)
The US Food and Drug Administration (FDA) has issued a marketing order authorising the sale of Philip Morris International (PMI)’s IQOS 3 holder and charger
US president-elect Joe Biden has unexpectedly named California attorney general Xavier Becerra as his choice for the vital role of heading the massive Health and Human Services (HHS) Department
A survey has concluded that reduced-risk claims for snus are understood by smokers, but better wording and genuine statements from independent sources – not tobacco companies – would improve their credibility
Nicotine and CBD are perceived as the bad guy and the good guy of health and wellness – but could putting the two together make commercial sense if it can help smokers break the habit?
The purchase by BAT of nicotine pouch brand Dryft to “strengthen” its modern oral portfolio in the US is an opportunity for both to increase their share of the market
Canada’s top health authority has issued a warning against nicotine pouches, saying they may pose “various serious health risks” to users, and ordered the recall of an unauthorised product being sold in Toronto
Altria’s oral tobacco portfolio drove the numbers of the Big Tobacco company, amid “uncertainties” caused by the COVID-19 pandemic
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the TobaccoIntelligence team.
